Biotech of the Week: Affibody and its Super antibodies from Scandinavia

From North Israel, we once again depart North towards Scandinavia to visit Sweden. On one of the several islands that make Stockholm a very particular and special European capital, our Biotech of the week Affibody has its headquarters.


affibody_logo_biotech_week

City: Stockholm (Sweden) – (actually just down the road from the Karolinska Institute)

Founded: 1998

Employees: 22 (as of 11/2015)

Financial Data: €5.3M Revenues (in 2015)

CEO: David Bejker

david_bejkar_affibody_biotech_mimetics

Mission: Affibody’s key platform is Affibody molecules, a novel class of antibody mimetics which due to their size surpass most monoclonal antibodies (mAbs) and antibody fragments in performance.

They are small sized (only 58 amino acid residues), extremely stable, low production cost, low background binding and a favourable patent situation.

Currently it is developing proprietary programs: 3 of them are therapeutically focused and target the prevention of Alzheimer’s disease, autoimmune disease and psoriasis (an autoimmune skin condition).  The 4th programme is oriented towards the imaging diagnosis of metastatic breast cancer (as it binds so strongly to the HER2 biomarker)


Comment: This platform reminds me of other antibody replacement platforms,  such as argenx, Ablynx (both in Belgium) or even Molecular Partners (Germany).

It’s extremely promising in theory, but clinical results have yet to show a significant outcome. Still, Affibody has several trials with promising clinical data already and could be one of the first European Biotechs to show the efficiency of such a new-generation platform…


Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.